dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Fernández Montes, Ana |
dc.contributor.author | Elez Fernandez, Mª Elena |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Martínez, N. |
dc.contributor.author | González, P. |
dc.contributor.author | Covela, M. |
dc.date.accessioned | 2022-09-06T12:27:43Z |
dc.date.available | 2022-09-06T12:27:43Z |
dc.date.issued | 2022-06 |
dc.identifier.citation | Fernández Montes A, Élez E, Vivancos A, Martínez N, González P, Covela M, et al. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer. Clin Transl Oncol. 2022 Jun;24:1209–14. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/8037 |
dc.description | Circulating tumor DNA; Liquid biopsy; Metastatic colorectal cancer |
dc.description.abstract | Purpose
Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications.
Methods
RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies).
Results
Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test).
Conclusion
Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;24 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer |
dc.subject | Recte - Càncer |
dc.subject | Clonatge molecular |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | Clone Cells |
dc.subject.mesh | Mutation |
dc.title | Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-021-02767-7 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | células clonales |
dc.subject.decs | mutación |
dc.relation.publishversion | https://doi.org/10.1007/s12094-021-02767-7 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Fernández Montes A] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. [Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vivancos A] Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Martínez N] Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain. [González P] Medical Oncology Department, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Covela M] Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain |
dc.identifier.pmid | 34997474 |
dc.identifier.wos | 000740217300002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |